Loading clinical trials...

BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia | Clinical Trials | Clareo Health

COMPLETEDPHASE3

BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia

Prospective, Multi-center, Randomized, Non-blind Trial to Assess the Efficacy and Safety of Moxifloxacin Versus Sulbactam/Ampicillin in the Treatment of Pulmonary Abscess and Aspiration Pneumonia

NCT01045902•Bayer

View on ClinicalTrials.gov

Summary

The purpose of this trial is to determine the efficacy and safety of Moxifloxacin in comparison to Sulbactam/Ampicillin in the treatment of pulmonary abscesses and aspiration pneumonia.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female patients aged 18 years or above
•The primary diagnosis is community or hospital acquired primary pulmonary abscess or aspiration pneumonia, requiring initial parenteral treatment

Exclusion Criteria

•Known hypersensitivity to fluoroquinolones and/or ß-lactams
•Patients with mechanical ventilation lasting more than 48 hours prior to enrollment, with poststenotic pneumonia, infarction pneumonia, pulmonary tuberculosis, lung abscess/pneumonia with concomitant endocarditis

Locations (15)

Mannheim, Baden-Wurttemberg, Germany

Nuremberg, Bavaria, Germany

Regensburg, Bavaria, Germany

Treuenbrietzen, Brandenburg, Germany

Frankfurt am Main, Hesse, Germany

Hildesheim, Lower Saxony, Germany

Rotenburg (Wümme), Lower Saxony, Germany

Lüdenscheid, North Rhine-Westphalia, Germany

Oberhausen, North Rhine-Westphalia, Germany

Paderborn, North Rhine-Westphalia, Germany

Key Dates

Start Date

February 1, 2001

Completion Date

January 1, 2005

Last Updated

January 11, 2010

Enrollment

139

ACTUAL participants

Conditions

Pneumonia, AspirationLung Abscess

Interventions

Avelox (Moxifloxacin, BAY12-8039)

DRUG

Sulbactam/Ampicillin

DRUG

The Clinical Application Value of "Showering Cells" in the Diagnosis of Aspiration Pneumonia

NCT07395310

Pneumonia, Aspiration

View study

TERMINATEDPHASE3

Inhaled Nitric Oxide Study for Respiratory Failure in Newborns

NCT00005776

Infant, NewbornHypertension, Pulmonary+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 11, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions